Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000761

Drug Information
SynonymsXabine; ZINC03806413; Ambap154361-50-9; Ro-09-1978/000; RG-340; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Ro 09-1978; C15H22FN3O6; Xeloda, Captabin, Capecitabine; HSDB 7656; R340; 158798-73-3; capecitabinum; CID60953; S1156_Selleck; CHEMBL1773; CAPECITABINE; DB01101; pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; LS-59070; Capecitabine [USAN]; R-340; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Xeloda; capecitabina; Capiibine; Capecitabine (JAN/USAN/INN); 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; Ro 09-1978/000; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; CHEBI:31348; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; 154361-50-9; AC1Q4KU8; C12650; C110904; Cytidine, 5'-deoxy-5-fluoro-N-((pentyloxy)carbonyl)-; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; FT-0082472; D01223; UNII-6804DJ8Z9U; Xeloda (TN); Caxeta; Capecitibine; AC1L1U83; Ro-09-1978; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Capecitabin; MolPort-005-938-254    
Trade NameXeloda    
IndicationBreast cancerPhase III    [1]
Colorectal cancer Approved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAntineoplastic Agents    
CAS NumberCAS 154361-50-9
PubChem Compound IDCID 60953.    
PubChem Substance IDSID 197173.    
SuperDrug ATC IDL01BC06;    
SuperDrug CAS ID154361509;    
TargetThymidylate synthaseInhibitor[2][3]
Thymidylate synthaseInhibitor[4]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2Roche. Product Development Pipeline. July 29 2009. To Reference
Ref 3Roche. Report of Roche. 2009. To Reference
Ref 4UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543